ID   IST-Mes2
AC   CVCL_1312
SY   IST-MES2; IST-MES-2; ISTMES2; IstMes2; Istituto Scientifico Tumori-Mesothelioma 2
DR   CLO; CLO_0006973
DR   CLDB; cl5544
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN10988152
DR   cancercelllines; CVCL_1312
DR   Cell_Model_Passport; SIDM01554
DR   DepMap; ACH-000331
DR   GEO; GSM887166
DR   GEO; GSM888238
DR   GEO; GSM1029450
DR   GEO; GSM1029451
DR   GEO; GSM1029452
DR   GEO; GSM1029453
DR   GEO; GSM1029454
DR   GEO; GSM1029455
DR   GEO; GSM1029456
DR   GEO; GSM1029457
DR   GEO; GSM1029458
DR   GEO; GSM1029459
DR   IARC_TP53; 28300
DR   ICLC; HTL01007
DR   LiGeA; CCLE_183
DR   PharmacoDB; ISTMES2_671_2019
DR   Progenetix; CVCL_1312
DR   Wikidata; Q54898348
RX   PubMed=10232421;
RX   PubMed=16704740;
RX   PubMed=22460905;
RX   PubMed=26589293;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Caucasian.
CC   HLA typing: A*24:02,26:01; B*38:01,39:01; C*12:03,12:03; DQA1*03:02,05:01; DQB1*02:02,02:02; DRB1*03:03,10:04 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (DepMap).
CC   Transformant: ChEBI; CHEBI:46661; Asbestos.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0.1%; East Asian, North=2.01%; East Asian, South=0%; South Asian=2.87%; European, North=43.48%; European, South=51.54% (PubMed=30894373).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ICLC
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 13
ST   D16S539: 11
ST   D21S11: 28,29
ST   D5S818: 12,13
ST   D7S820: 10
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C45662; Pleural epithelioid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   71Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 24
//
RX   PubMed=10232421; DOI=10.1183/09031936.99.13352799;
RA   Orengo A.M., Spoletini L., Procopio A., Favoni R.E., De Cupis A.,
RA   Ardizzoni A., Castagneto B., Ribotta M., Betta P.G., Ferrini S.,
RA   Mutti L.;
RT   "Establishment of four new mesothelioma cell lines: characterization
RT   by ultrastructural and immunophenotypic analysis.";
RL   Eur. Respir. J. 13:527-534(1999).
//
RX   PubMed=16704740; DOI=10.1186/1471-2407-6-130;
RA   Martarelli D., Catalano A., Procopio A., Orecchia S., Libener R.,
RA   Santoni G.;
RT   "Characterization of human malignant mesothelioma cell lines
RT   orthotopically implanted in the pleural cavity of immunodeficient mice
RT   for their ability to grow and form metastasis.";
RL   BMC Cancer 6:130.1-130.7(2006).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//